万古霉素所致类过敏与过敏反应的鉴别研究进展

doi:10.19803/j.1672-8629.20220630

中国药物警戒 ›› 2023, Vol. 20 ›› Issue (9): 1078-1080.
DOI: 10.19803/j.1672-8629.20220630

• 综述 • 上一篇

万古霉素所致类过敏与过敏反应的鉴别研究进展

臧天颖, 刘炳阳, 唐晓军^*

中国医学科学院北京协和医学院整形外科医院颅颌面三科,北京 100144

收稿日期:2022-10-28 出版日期:2023-09-15 发布日期:2023-09-14
通讯作者: ^*唐晓军,男,博士,教授,颅颌面外科。E-mail:frog30@126.com
作者简介:臧天颖,女,硕士,颅颌面外科。
基金资助:
中国医学科学院整形外科医院重大项目基金资助（120087）; 西宁市科技局民生科技专项科技局直补项目（2019-M-12）

Differentiation of vancomycin induced anaphylactoid and anaphylactic reactions

ZANG Tianying, LIU Bingyang, TANG Xiaojun^*

Maxillo-facial Surgery Center, Plastic Surgery Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing 100144, China

Received:2022-10-28 Online:2023-09-15 Published:2023-09-14

摘要/Abstract

摘要： 万古霉素（vancomycin）属于糖肽类抗生素,临床应用十分广泛,是治疗耐药性革兰阳性菌感染最有效的抗生素之一,其控制难治性感染的同时,也可能带来多种不良反应。其中,以红人综合征（red man syndrome, RMS）为代表的类过敏反应、Ig-E介导的超敏反应即过敏反应发生率均较高,临床后果严重,且两者临床表现、诊断方式类似,均需及时识别、干预。但2种反应发生后的治疗方法及后续是否可继续应用万古霉素有所不同,因此两者的预防、诊断及鉴别诊断十分重要。针对RMS、Ig-E介导的超敏反应的异同,本文回顾了既往相关文献,并对两者的临床表现、鉴别诊断、高风险人群识别、预防方式、治疗措施做出综述。

关键词: 万古霉素, 红人综合征, 类过敏反应, Ig-E介导的超敏反应, 过敏反应, 药品不良反应

Abstract: Vancomycin is a glycopeptide antibiotic, which is widely used in clinic. It is one of the most effective antibiotics for drug-resistant gram-positive bacterial infections. It can control refractory infections, but may also induce a variety of side effects. For example, the incidence of anaphylactoid reactions represented by Red Man Syndrome (RMS) and Ig-E mediated hypersensitivity reactions is high, and the clinical consequences are serious. Moreover, the clinical manifestations and diagnostic methods of the two are similar, which requires quick identification and intervention. However, the treatment methods following the two types of reactions vary and whether vancomycin can continue to be used depends on the conditions of patients, so the prevention, diagnosis and differential diagnosis of the two types of side effects are very important. With regard to the similarities and differences between RMS and Ig-E mediated hypersensitivity, this article reviews the related literature and outlines the clinical manifestations, differential diagnosis, identification of high-risk populations, prevention methods, and treatments.

Key words: vancomycin, red man syndrome, anaphylactoid reaction, Ig-E mediated hypersensitivity reaction, anaphylaxis, adverse drug reactions

中图分类号:

R978
R994

臧天颖, 刘炳阳, 唐晓军. 万古霉素所致类过敏与过敏反应的鉴别研究进展[J]. 中国药物警戒, 2023, 20(9): 1078-1080.

ZANG Tianying, LIU Bingyang, TANG Xiaojun. Differentiation of vancomycin induced anaphylactoid and anaphylactic reactions[J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 1078-1080.

参考文献

[1] ROTHENBERG HJ.Anaphylactoid reaction to vancomycin[J]. J Am Med Assoc, 1959, 171: 1101-1102.
[2] GARRELTS JC, PETERIE JD.Vancomycin and the“red man's syndrome”[J]. N Engl J Med, 1985, 312: 245.
[3] ARROYO-MERCADO F, KHUDYAKOV A, CHAWLA GS, et al.Red man syndrome with oral vancomycin: a case report[J]. Am J Med Case Rep, 2019, 7(1): 16-17.
[4] DEWEESE R, SLAVENS J, BARUA A, et al.Vancomycin-induced eosinophilic peritonitis[J]. Am J Health Syst Pharm, 2016, 73(9): e243-e246.
[5] ALVAREZ-ARANGO S, OGUNWOLE SM, SEQUIST TD, et al.Vancomycin infusion reaction - moving beyond “red man syndrome”[J]. N Engl J Med, 2021, 384(14): 1283-1286.
[6] APUYA J, KLEIN EF.Stridor accompanying red man's syndrome following perioperative administration of vancomycin[J]. J Clin Anesth, 2009, 21(8): 606-608.
[7] ALVAREZ-ARANGO S, YERNENI S, TANG O, et al.Vancomycin hypersensitivity reactions documented in electronic health records[J]. J Allergy Clin Immunol Pract, 2021, 9(2): 906-912.
[8] POLK RE, HEALY DP, SCHWARTZ LB, et al.Vancomycin and the red-man syndrome: pharmacodynamics of histamine release[J]. J Infect Dis, 1988, 157(3): 502-507.
[9] HEALY DP, SAHAI JV, FULLER SH, et al.Vancomycin-induced histamine release and “red man syndrome”: comparison of 1 and 2 hour infusions[J]. Antimicrob Agents Chemother, 1990, 34(4): 5504.
[10] POLK RE, ISRAEL D, WANG J, et al.Vancomycin skin tests and prediction of “red man syndrome” in healthy volunteers[J]. Antimicrob Agents Chemother, 1993, 37(10): 2139-2143.
[11] BROYLES AD, BANERJI A, BARMETTLER S, et al.Practical guidance for the evaluation and management of drug hypersensitivity: specific drugs[J]. J Allergy Clin Immunol Pract, 2020, 8(9S): S16-S116.
[12] VITTE J, AMADEI L, GOUITAA M, et al.Paired acute-baseline serum tryptase levels in perioperative anaphylaxis: an observational study[J]. Allergy, 2019, 74(6): 1157-1165.
[13] XU Y, CHEN G. Mast cell and autoimmune diseases[J/OL]. [2022-10-01]. http://dx.doi.org/10.1155/2015/246126.
[14] RENZ CL, THURN JD, FINN HA, et al.Oral antihistamines reduce the side effects from rapid vancomycin infusion[J]. Anesth Analg, 1998, 87(3): 681-685.
[15] VALENT P, AKIN C, AROCK M, et al.Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposal[J]. Int Arch Allergy Immuno, 2012, 157(3): 215-225.
[16] ANICETO V, DIAS MM, MELO JML, et al.Serum baseline tryptase level as a marker for the severity of anaphylaxis[J]. Int Arch Allergy Immunol, 2019, 179(3): 201-208.
[17] OTANI IM, KUHLEN JL JR, BLUMENTHAL KG, et al.A role for vancomycin epicutaneous skin testing in the evaluation of perioperative anaphylaxis[J]. J Allergy Clin Immunol Pract, 2015, 3(6): 984-985.
[18] MYERS AL, GAEDIGK A, DAI H, et al.Defining risk factors for red man syndrome in children and adults[J]. Pediatr Infect Dis J, 2012, 31(5): 464-468.
[19] NEWFIELD P, ROIZEN MF.Hazards of rapid administration of vancomycin[J]. Ann Intern Med, 1979, 91(4): 581.
[20] SIVAGNANAM S, DELEU D.Red man syndrome[J]. Crit Care, 2003, 7(2): 119-120.
[21] LIN SK, MULIERI KM, ISHMAEL FT.Characterization of vancomycin reactions and linezolid utilization in the pediatric population[J]. J Allergy Clin Immunol Pract, 2017, 5(3): 750-756.
[22] MCNEIL BD, PUNDIR P, MEEKER S, et al.Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions[J]. Nature, 2015, 519(7542): 237-241.
[23] GAUDENZIO N, SIBILANO R, MARICHAL T, et al.Different activation signals induce distinct mast cell degranulation strategies[J]. J Clin Invest, 2016, 126(10): 3981-3998.
[24] MCNEIL BD, PUNDIR P, MEEKER S, et al.Identification of a mast-cell-specific receptor crucial for pseudo-allergic drug reactions[J]. Nature, 2015, 519(7542): 237-241.
[25] BABINA M, GUHL S, ARTUC M, et al.Allergic FcεRI- and pseudo-allergic MRGPRX2-triggered mast cell activation routes are independent and inversely regulated by SCF[J]. Allergy, 2017, 73(1): 256-260.

万古霉素所致类过敏与过敏反应的鉴别研究进展

Differentiation of vancomycin induced anaphylactoid and anaphylactic reactions

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	李娜, 郭军, 郭文佳, 吕茵茵, 李彩宏, 牟向东. 奥马珠单抗注射剂治疗哮喘致迟发型皮肤过敏反应1 例分析[J]. 中国药物警戒, 2024, 21(2): 211-212.
[7]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[8]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[9]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[10]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[11]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[12]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[13]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[14]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[15]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.